Table 2.
Univariate and multivariate survival analysis in all patients (n = 107)
| Different variables | Progression-free survival | Overall survival | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||||||
| MST | HR (95% CI) | p-value | HR | 95% CI | p-value | MST | HR (95% CI) | p-value | HR | 95% CI | p-value | ||
| Age | < 75/ ≥ 75 years | 324/251 | 1.14 (0.73–1.80) | 0.55 | 441/568 | 0.98 (0.60–1.61) | 0.92 | ||||||
| Gender | Male/female | 281/270 |
0.99 (0.54–1.80) |
0.94 | 418/829 | 1.62 (0.84–3.13) | 0.22 | ||||||
| ECOG PS | 0–1/2–3 | 324/209 | 2.03 (1.13–3.67) | 0.09 | 1.28 | 0.94–1.74 | 0.11 | 731/169 | 2.75 (1.47–5.14) | < 0.01 | 1.59 | 1.14–2.21 | < 0.01 |
| Smoking (BI) | < 900/ ≥ 900 | 234/324 | 0.79 (0.51–1.23) | 0.33 | 521/568 | 0.94 (0.58–1.53) | 0.84 | ||||||
| Histology | AC/Non-AC | 388/244 | 1.68 (1.08–2.61) | 0.01 | 0.73 | 0.56–0.94 | < 0.01 | 813/372 | 1.42 (0.88–2.31) | 0.06 | 0.83 | 0.63–1.08 | 0.16 |
| Brain metastasis | Yes/No | 470/234 | 1.30 (0.81–2.07) | 0.18 | 522/437 | 1.26 (0.75–2.13) | 0.22 | ||||||
| Bone metastasis | Yes/No | 244/307 | 1.21 (0.71–2.06) | 0.40 | 522/521 | 1.05 (0.60–1/83) | 0.64 | ||||||
| Prior RT | Yes/No | 324/251 | 1.08 (0.67–1.75) | 0.97 | 472/581 | 1.16 (0.69–1.93) | 0.83 | ||||||
| CRP | High/Low | 209/324 | 1.51 (0.96–2.36) | 0.09 | 0.97 | 0.74–1.25 | 0.86 | 364/731 | 1.79 (1.10–2.91) | 0.02 | 1.01 | 0.73–1.39 | 0.93 |
| Albumin | High/Low | 303/251 | 1.51 (0.97–2.35) | 0.08 | 0.96 | 0.74–1.25 | 0.79 | 829/364 | 1.84 (1.13–2.98) | 0.01 | 0.88 | 0.65–1.19 | 0.42 |
| Lymphocyte | High/Low | 251/281 | 1.02 (0.66–1.58) | 0.91 | 441/521 | 1.07 (0.66–1.73) | 0.95 | ||||||
| PD-L1 expression | 1–49/50–100% | 240/324 | 1.01 (0.60–169) | 0.82 | 441/521 | 0.97 (0.55–1.72) | 0.99 | ||||||
| Intratumoral PD-1 | High/Low | 234/303 | 1.27 (0.74–2.15) | 0.63 | 372/568 | 1.38 (0.77–2.46) | 0.22 | ||||||
| Intratumoral CD4 | High/Low | 303/281 | 1.07 (0.68–1.68) | 0.74 | 522/441 | 1.19 (0.72–1.95) | 0.48 | ||||||
| Intratumoral CD8 | High/Low | 336/209 | 1.28 (0.81–2.02) | 0.26 | 731/333 | 1.81 (1.09–3.01) | 0.01 | 0.70 | 0.53–0.92 | 0.01 | |||
| Intratumoral Foxp3 | High/Low | 307/281 | 1.43 (0.91–2.24) | 0.12 | 522/472 | 1.13 (0.68–1.86) | 0.62 | ||||||
| Stromal PD-1 | High/Low | 234/307 | 1.17 (0.71–1.93) | 0.24 | 372/568 | 1.21 (0.71–2.05) | 0.41 | ||||||
| Stromal CD4 | High/Low | 336/204 | 1.72 (1.09–2.69) | 0.01 | 0.79 | 0.62–0.99 | 0.04 | 731/333 | 1.92 (1.16–3.16) | 0.01 | 0.89 | 0.67–1.18 | 0.44 |
| Stromal CD8 | High/Low | 303/251 | 0.85 (0.54–1.34) | 0.50 | 521/472 | 1.16 (0.68–1.83) | 0.65 | ||||||
| Stromal Foxp3 | High/Low | 324/251 | 1.34 (0.86–2.11) | 0.19 | 522/472 | 0.98 (0.59–1.61) | 0.94 | ||||||
Bold values indicate statistically significant p values (p < 0.05)
MST median survival time (days), ECOG PS eastern cooperative oncology group performance status, BI brinkman index, AC adenocarcinoma, non-AC non-adenocarcinoma, prior RT radiation before initial pembrolizumab, CRP C-reactive protein, PD-L1 programmed death ligand-1, PD-1 programmed death-1, HR hazard ratio, 95% CI 95% confidence interval